Skip to main content
AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc. — Investor Relations & Filings

Ticker · ANTX ISIN · US0373261058 US Manufacturing
Open in API
Filings indexed 339 across all filing types
Latest filing 2023-08-25 Director's Dealing
Country US United States of America
Listing US ANTX

About AN2 Therapeutics, Inc.

https://www.an2therapeutics.com/

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing treatments for rare, chronic, and serious infectious diseases with high unmet medical needs. The company utilizes its proprietary boron chemistry platform to create novel small molecule therapeutics. Its development pipeline includes boron-based compounds, such as its lead candidate epetraborole, which are being investigated as potential first-in-class or best-in-class therapies. The company's mission is to deliver high-impact drugs to improve global health outcomes, with potential applications extending to oncology.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2023-08-25 English
4
Director's Dealing
2023-08-25 English
Regulatory Filings 2023
Regulatory Filings
2023-08-23 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-08-22 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and other related disclosures typical of a securities offering document. It is not a financial report, earnings release, management discussion, or any other type of corporate filing listed in the definitions. The document is a capital markets filing related to financing activities, specifically a stock offering prospectus supplement. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus supplement, not just an announcement or a brief notice.
2023-08-16 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 15, 2023, reporting the entry into a material definitive agreement related to an underwritten offering of common stock. It details the underwriting agreement, the number of shares offered, the offering price, and the gross proceeds expected. It also includes references to exhibits such as the underwriting agreement and a press release announcing the pricing of the offering. The content focuses on a financing transaction and capital raising activity. There are no financial statements or earnings data presented, nor is this a full annual or quarterly report. The primary subject is the update on the company's capital raising through a stock offering, which fits the category of Capital/Financing Update.
2023-08-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.